Hologic, a women's health company, has signed a definitive agreement to acquire Reveal Genomics, a Barcelona-based precision oncology company. Financial terms were not disclosed. Reveal Genomics develops genomic tests to personalise cancer treatment, including HER2DX, which helps optimise therapy for patients with HER2-positive breast cancer. The tests complement Hologic's Breast Cancer Index (BCI) test, which informs decisions on extended endocrine therapy in women with HR+ early-stage breast cancer. Vitor Rocha, chief executive officer of Diagnostic Solutions at Hologic, said the deal would help it "support even more women diagnosed with breast cancer." Patricia Villagrasa-Gonzalez, Reveal Genomics' chief executive officer and co-founder, said Hologic gives it the scale to reach more patients worldwide. Completion depends on Spanish regulatory approval and other customary closing conditions.

Join Scarborough Health Network at the Breast Screening and awareness event. 14 October 2026 In partnership with the Olive Branch of Hope, Scarborough Health Network (SHN) is holding its next annual event for Breast Cancer Awareness Month, focused on getting its community screened for breast cancer and raising awareness about breast health. Join Scarborough Health Network for a FREE community event dedicated to empowering women with knowledge, advocacy, and access. You can schedule your mammogram for any time between 7:30 a.m. and 3:30 p.m. and enjoy refreshments, giveaways, and an optional education session. Not ready to schedule a mammogram, but interested in learning more about breast health? The three education sessions are at 9 a.m., 11 a.m., and 1:30 p.m. These have limited capacity and first priority will be given to those who have scheduled mammograms. Remaining spots will be filled on a first-come, first-served basis. Through insightful conversations with physicians, patients with lived experience, and community advocates, Scarborough Health Network'll provide vital breast health education - from how to self-screen, triple negative breast cancer, and high risk factors - and how awareness can change outcomes. All are welcome. What to expect. * On-site screening mammograms with female healthcare professionals (for those who qualify) * Discussions on breast health including high risk factors * Complimentary refreshments * Giveaways * Free Parking (vouchers will be provided) Why attend. * Gain essential knowledge about breast health and when you can start self-referring * Access screening, support, and community resources * Connect with a community focused on empowerment and wellness Mammogram screenings. If you are interested in receiving a mammogram during the event, bringing your health card is required. Individuals who are between 40-74 years of age can self-refer and enroll in the Ontario Breast Screening Program (OBSP), where screening mammograms typically are performed every 2 years. Together, Scarborough Health Network is raising awareness and reclaiming its health to protect generations to come. This event is hosted by SHN in partnership with The Olive Branch of Hope, Black Physicians' Association of Ontario, TAIBU Community Health Centre, Scarborough Ontario Health Team, Scarborough Centre for Healthy Communities, Hologic, Novartis, Siemens Healthineers, and Toronto Central Regional Cancer Centre.

Hologic's Fluent(R) Pro system wins International Design Excellence Award for user-centric innovation in women's health. September 4, 2026 Technology honored for design that helps simplify fluid management and visualization during hysteroscopic procedures MARLBOROUGH, Mass. - Hologic, a global leader in women's health, has been honored with an International Design Excellence Award (IDEA) for its Fluent Pro fluid management system, which supports visualization and fluid control during hysteroscopy. "This award reflects our team's dedication to thoughtful design, clinical partnership and continuous innovation," said Brandon Schnittker, CEO, GYN Surgical Solutions. "Our goal has always been to help serve more patients while continuing to meet the evolving needs of our customers. The Fluent Pro system is a strong example of how purposeful, user-centric design can make complex procedures feel simpler and more intuitive for the teams who rely on our technologies every day." Presented annually by the Industrial Designers Society of America (IDSA), one of the longest-standing and largest industrial design associations in existence, the International Design Excellence Awards recognize design excellence across industries and disciplines. This year the organization received more than 2,000 entries. The Fluent Pro system is designed to deliver seamless integration and an intuitive user experience that supports procedural performance, including during procedures that use the MyoSure(R) tissue removal system, a device that removes fibroids and polyps through hysteroscopy. The user interface provides setup, operation and troubleshooting help screens that are easily accessible throughout the procedure. The system also provides suction control to resect simple to complex types of pathology designed for improved MyoSure procedures. The Fluent Pro interface aims to support the broader operating room team, including physicians performing procedures and nursing staff coordinating setup and room flow. Its user-centric design reflects the realities of the clinical environment, helping physicians stay focused on patient care and procedural execution. The system is also designed to simplify workflows and help teams operate with greater consistency and confidence. More than 1,020 hospital systems across the United States use the Fluent Pro system, allowing clinical teams nationwide to benefit from this award-winning technology. About Hologic, Inc. Hologic, Inc. is a global leader in women's health dedicated to developing innovative medical technologies that effectively detect, diagnose and treat health conditions and raise the standard of care around the world. To learn more, visit www.hologic.com and connect with us on LinkedIn, Facebook, X, Instagram and YouTube. Forward-Looking Statements This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based. Hologic, Fluent and MyoSure are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. Notes and Disclaimers Important Safety Information The Fluent(R) Pro fluid management system is intended to provide liquid distension of the uterus during diagnostic and operative hysteroscopy, and to monitor the volume differential between the irrigation liquid flowing into and out of the uterus while providing drive, control and suction for hysteroscopic morcellators, specifically for the MyoSure(R) tissue removal device. The Fluent Pro fluid management system may not be used to introduce fluids into the uterus when hysteroscopy is contraindicated. The system should not be used to remove pathologies from pregnant patients or patients exhibiting pelvic infection, cervical malignancies, or previously diagnosed endometrial cancer. For detailed benefit and risk information, please consult the Instructions For Use. Media Contact: Bridget Perry Senior Director, Corporate Communications (+1) 508.263.8654 [email protected]